SUMMARY Osteocalcin, a vitamin K dependent protein synthesised by osteoblasts, was measured in serum by radioimmunoassay in patients with rheumatoid arthritis (n=36) and seronegative spondyloarthropathies (n=23). The serum osteocalcin levels were decreased in both patient groups compared with the levels measured in age and sex matched healthy controls. We found no relation between serum osteocalcin and the disease duration or inflammatory activity of the patients who were without drug treatment at the first examination. After administration of glucocorticoids (20 mg prednisolone a day) circulating osteocalcin decreased significantly after one week of treatment. During gradual reduction of the steroid dosage osteocalcin returned to pretreatment values. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) did not influence circulating osteocalcin. During treatment with chloroquine or penicillamine serum osteocalcin increased significantly, concomitant with a reduction of the acute phase reactants. Controversy persists about the abnormality of bone turnover in rheumatic diseases, but our data suggest that the overall bone turnover is decreased in patients with rheumatoid arthritis and other inflammatory arthritides.
Previous studies have suggested that patients with rheumatoid arthritis (RA) may suffer not only from periarticular but also generalised alteration in bone metabolism.' 2 The propensity for the development of osteoporosis in rheumatoid arthritis is still a poorly understood phenomenon but is probably due to a number of factors; the inflammatory disease itself, prolonged immobility, and corticosteroid treatment can all be expected to favour the development of osteopenia. Radiological methods have generally been employed to determine the degree of bone loss occurring in RA. Since these methods lack satisfactory sensitivity there has been a search for other techniques; whole body retention of 99mTc diphosphonate3 4 In this study we have measured the circulating levels of osteocalcin in inflammatory rheumatic diseases in an attempt to elucidate the metabolic activity of bone in these disorders and the possible effect of antirheumatic drugs on bone turnover. The vitamin K dependent protein osteocalcin is the most abundant non-collagenous protein in bone6 7 and is probably synthesised only by osteoblasts. group.bmj.com on June 27, 2017 -Published by http://ard.bmj.com/ Downloaded from amount was 0-3 jg/l. In order to study the possible interaction of osteocalcin substances in the osteocalcin assay serum dilution curves were constructed and compared with a standard curve. Parallel serum and standard curves were achieved, indicating an adequate specificity of the determinations (Fig. 1) .
The logarithmic values of serum osteocalcin were used when comparing groups and for correlative analyses since highly skewed distributions of osteocalcin were observed in the patient groups. Osteocalcin values were distributed normally in the controls as were log transformed osteocalcin values in patients and controls.
The serum concentrations (reference ranges in parentheses) of haptoglobin (0.2-2.0 g/l), creatinine (64-106 ,umol/l), albumin modified calcium (2-0-2.6 mmol/l), and alkaline phosphatase (0 8-48 [tkat/l)
were measured at the Department of Clinical Chemistry, University Hospital, Uppsala.
Wilcoxon's rank sum and signed rank tests were used for statistical analyses.
Results
Female patients with rheumatoid arthritis or other inflammatory arthritides had a geometric mean (SD range) serum osteocalcin value of 1.5 (0.6-4-0) .tg/l, which was a level significantly reduced (p<O-OOl) compared with that found in age matched healthy female controls (mean value (SD range) 3 (1-5-3-9) ,ug/l, which was significantly decreased (p<0-01) compared with that of age matched male controls with a mean value of 3-5 (2-6&4-7) Rg/l. Fig. 2 shows the mean osteocalcin levels in male and female patients subgrouped into rheumatoid arthritis and seronegative arthropathies. Significantly reduced osteocalcin levels were found in female patients with rheumatoid arthritis (p<0001) and other inflammatory arthritides (p<0-01) compared with those in the female controls. Significantly reduced osteocalcin values were also seen in male patients with rheumatoid arthritis (p<0.05) and seronegative arthropathies (p<001) compared with the values for male controls. Similar (p> 0.05) osteocalcin levels and a similar (p> 0.05) degree of inflammatory activity, defined by serum haptoglobin and erythrocyte sedimentation rate (ESR), were noted in the female or male patient subgroups (Table 1) .
No correlations were found between osteocalcin levels and ESR or serum haptoglobin values. This was valid when calculations were performed on the whole patient population or groups of patients subdivided with respect to diagnosis, sex, and age (greater or less than 50 years old). This age was used in data handling since after the menopause hi0her serum osteocalcin concentrations are reported.314 There was a significant correlation between serum osteocalcin and serum alkaline phosphatase only in female patients less than 50 years old (n= 10, 
r=0.62, p<005). All the patients and controls had normal renal function as estimated by serum creatinine measurements. Their albumin modified serum calcium values were within the normal ranges.
The acute effects on serum osteocalcin during treatment with glucocorticoids are illustrated in Fig. 3 . After one week of daily administration of 20 mg prednisolone the osteocalcin levels (mean (SEM range)) decreased from 1-6 (1. 3-2-0) to 1-0 (0.8-1-3) [tg/l (p<O0Ol). A similar decrease was observed in three patients given ACTH 30 IU/day (Fig. 3) . During gradual reduction of the steroid dosage to 5-7.5 mg prednisolone/day the osteocalcin levels returned to pretreatment levels. The same pattern was seen irrespective of whether the steroids were given alone or combined with azathioprine (100 mg/day) or cyclophosphamide (50-100 mg/day) (Fig. 4) . At the start of the study the mean alkaline phosphatase level in the steroid treated group was ACTH Fig. 3 The osteocalcin levels in patients with rheumatoid arthritis (n=9) and seronegative spondyloarthropathies (n=4) before and after one week of treatment with prednisolone 20 mg/day (-*). The uptake of 99mTc pyrophosphate has also been reported to be increased in bones remote from the area of active synovitis,' suggesting that patients with rheumatoid arthritis may have a generalised skeletal defect in addition to the juxtaarticular osteoporosis. The significance of increased radiopharmaceutical uptake has not been fully explained but it has been claimed to reflect an increased bone turnover in rheumatoid arthritis. -5 The mechanisms underlying reduced circulating osteocalcin in arthritic conditions are not known and any theory regarding the possible association with altered bone metabolism must be of a highly speculative nature. We found no relation between serum osteocalcin and duration or inflammatory activity of the disease defined by ESR and acute 2 9±0 3 (SEM) .tkat/l and remained at the same level after three months (2.8±0.3) and nine months of treatment (2-9±0.3).
Seven patients were studied serially during chloroquine treatment (Fig. 5) . Serum osteocalcin (mean (SEM range)) at the start of the study was 3 1 (2.6-3-7) Rg/l and increased significantly (p<001) after three months on therapy to 4 4 (3.8-5-1) sg/l and after another six months to 4.8 (4-1-5.6) p.g/l (p<0-01). An increase, which did not reach significance (p> 0.05), was also observed for alkaline phosphatase from 3*0±0*3 (SEM) [tkatIl to 3-2±0 3 [skat/l at three months and 3 3±0 4 [skat/l at nine months. The same pattern was observed in patients (n=6) treated with penicillamine (Fig. 5) , i.e., a significant increase (p<005) of serum osteocalcin from 1-5 (1(0-2.2) Rtg/l to 2-2 (1.6-3.1) [tg/l at three months and 2-8 (2.3-3.4) [sg/l at nine months after institution of the drug. At these observation times the mean alkaline phosphatase level was 2 9±0 4, 3-2±0 5, and 3-4±0 7 !kat/l. This increase was not significant (p>005). 
